The Down Syndrome market report also offers comprehensive insights into the Down Syndrome market size, share, Down Syndrome epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Down Syndrome market size growth forward.
Some of the key highlights from the Down Syndrome Market Insights Report:
Several key pharmaceutical companies, including Eisai, AC Immune, Elixirgen Therapeutics, Aphios Therapeutics, Avanti Biosciences, Annovis Bio, AelisFarma, Kinopharma, NeuroNascent, Pharmasum Therapeutics, and others, are developing novel products to improve the Down Syndrome treatment outlook.
The total Down Syndrome market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.
As per DelveInsight analysis, the Down Syndrome market is anticipated to witness growth at a considerable CAGR
Down’s syndrome is a genetic condition caused by an error in cell division known as nondisjunction, which results in an individual having a full or partial extra copy of chromosome 21. This additional genetic material disrupts normal development, leading to the characteristic physical and intellectual traits associated with Down’s syndrome.
In 2023, the market size for Down’s syndrome in the United States was estimated at approximately USD 241 million. That same year, the U.S. had around 220,000 prevalent cases of Down’s syndrome. The condition is more commonly diagnosed in females than in males.
There are three main types of Down’s syndrome: Trisomy 21, Robertsonian translocation, and Mosaicism. In 2023, Trisomy 21 accounted for the largest share of cases across the 7MM (United States, EU5, Japan, and China).
While there is no single, standardized treatment for Down’s syndrome, care is tailored to the individual’s physical and intellectual needs, focusing on their strengths and limitations. Many individuals with Down’s syndrome can receive effective care while living at home or within their communities.
In February 2021, the ICOD project received EUR 6 million in funding from the European Commission to support the clinical development of AEF0217, a treatment aimed at addressing cognitive deficits associated with Down’s syndrome.
According to the Global Down’s Syndrome Foundation, there are rare forms of Down’s syndrome—translocation Down’s syndrome and mosaic Down’s syndrome—which account for less than 6% of all cases. In these forms, not all of the chromosomes are triplicated, or not all of the body’s cells carry the extra chromosome.
In 2023, the United States had nearly 220,000 prevalent cases of Down’s syndrome. The distribution of prevalent cases by age is categorized into three groups: 0-18 years, 19-40 years, 41-60 years, and over 60 years. Among these, the 0-18 years age group accounted for the highest number of cases in the U.S.
Down’s syndrome is more common in females than in males.
Prevalent cases of Down’s syndrome are also categorized by clinical manifestations, which include cardiac, hearing, vision, respiratory, autoimmune, neurological disorders, and other clinical issues. Among these, hearing problems were the most commonly reported clinical manifestation in the U.S. in 2023.
Strategise your business goals by understanding market dynamics @ Down Syndrome Market Landscape
Down Syndrome Overview
Down syndrome is a genetic condition caused by the presence of an extra copy of chromosome 21 (trisomy 21), rather than the usual two copies. This chromosomal abnormality leads to intellectual disability, which can range from mild to moderate, and is often accompanied by distinct physical features, such as a characteristic facial appearance with a small nose and an upward slant to the eyes, as well as low muscle tone in infancy.
Individuals with Down syndrome may also be born with a variety of health concerns, including heart defects, digestive issues, and short stature. A common physical trait is a single deep crease across the center of the palm. Additionally, people with Down syndrome face an increased risk of developing conditions such as gastroesophageal reflux, celiac disease, hypothyroidism, hearing and vision problems, leukemia, and Alzheimer’s disease later in life.
Down syndrome is usually not inherited, as it occurs due to an error in cell division during the formation of the egg or sperm. While there is no cure for Down syndrome, treatment focuses on addressing the specific symptoms and health concerns of each individual. Research is ongoing to better understand the genes involved in the condition, with the goal of developing more effective treatments in the future.
Do you know the treatment paradigms for different countries? Download our Down Syndrome Market Sample Report
Down Syndrome Epidemiology Segmentation
DelveInsight’s Down Syndrome market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Down Syndrome historical patient pools and forecasted Down Syndrome patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Down Syndrome Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:
Down Syndrome Prevalence
Age-Specific Down Syndrome Prevalence
Gender-Specific Down Syndrome Prevalence
Diagnosed and Treatable Cases of Down Syndrome
Visit for more @ Down Syndrome Epidemiological Insights
Down Syndrome Treatment Market
The Down Syndrome market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Down Syndrome market trends by analyzing the impact of current Down Syndrome therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Down Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Down Syndrome market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Down Syndrome market in 7MM is expected to witness a major change in the study period 2020-2034.
Down Syndrome Key Companies
Eisai, AC Immune, Elixirgen Therapeutics, Aphios Therapeutics, Avanti Biosciences, Annovis Bio, AelisFarma, Kinopharma, NeuroNascent, Pharmasum Therapeutics
For more information, visit Down Syndrome Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Down Syndrome Market Report:
11 Years Forecast
7MM Coverage
Descriptive overview of Down Syndrome, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Down Syndrome epidemiology in the 7MM
Down Syndrome marketed and emerging therapies
Down Syndrome companies
Down Syndrome market drivers and barriers
Key Questions Answered in the Down Syndrome Market Report 2034:
What was the Down Syndrome market share distribution in 2020, and how would it appear in 2034?
What is the total Down Syndrome market size and the market size by therapy across the 7MM for the study period (2020-32)?
What are the important findings from 7MM, and which country will have the greatest Down Syndrome market size from 2020-32?
During the study period (2020-2034), at what CAGR is the Down Syndrome market projected to expand at 7MM?
Table of Contents:
1 Down Syndrome Market Key Comprehensive Insights
2 Down Syndrome Market Report Introduction
3 Competitive Intelligence Analysis for Down Syndrome
4 Down Syndrome Market Analysis Overview at a Glance
5 Executive Summary of Down Syndrome
6 Down Syndrome Epidemiology and Market Methodology
7 Down Syndrome Epidemiology and Patient Population
8 Down Syndrome Patient Journey
9 Down Syndrome Treatment Algorithm, Down Syndrome Current Treatment, and Medical Practices
10 Key Endpoints in Down Syndrome Clinical Trials
11 Down Syndrome Marketed Therapies
12 Down Syndrome Emerging Therapies
13 Down Syndrome: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Down Syndrome
16 Down Syndrome Market Key Opinion Leaders Reviews
18 Down Syndrome Market Drivers
19 Down Syndrome Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Down Syndrome Epidemiology 2034
DelveInsight’s “Down Syndrome – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Down Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Down Syndrome Pipeline 2024
“Down Syndrome Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Down Syndrome market. A detailed picture of the Down Syndrome pipeline landscape is provided, which includes the disease overview and Down Syndrome treatment guidelines.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
